BLRX : Summary for BioLineRx Ltd. - American Depos - Yahoo Finance

U.S. Markets closed

BioLine Rx Ltd (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.93+0.01 (+0.89%)
At close: 4:00PM EST
People also watch
CANFCPRXAVEOAPRIBIOC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.92
Open0.93
Bid0.75 x 200
Ask0.99 x 2000
Day's Range0.88 - 0.93
52 Week Range0.83 - 1.42
Volume50,550
Avg. Volume130,946
Market Cap54.45M
Beta-0.24
PE Ratio (TTM)-3.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
    Zacks2 days ago

    BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

    BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

  • PR Newswire4 days ago

    BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

    TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is part of a research collaboration between MSD and MD Anderson Cancer Center. The open-label, single center, single-arm Phase 2a study aims to evaluate the potential of BL-8040 in combination with KEYTRUDA in pancreatic cancer and focuses on the mechanism-of-action by which both drugs might synergize.

  • PR Newswire17 days ago

    BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco

    BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin, will be presenting at the Biotech Showcase 2017 Conference being held in San Francisco, CA. The BioLineRx presentation is scheduled to start at 2:30 pm PST on Tuesday, January 10, 2017. A live audio webcast of the presentation will be available online at BioLineRx's investor web page.